amaxa eNews #5 amaxa biosystems
  Issue:
Article:
ContactLegal
Welcome to amaxa eNews #5!

This issue provides you with an update on the most recent developments in Nucleofector Technology supporting cancer research. Enjoy reading!

And if you like amaxa eNews please recommend it to your friends and colleagues.

Your amaxa team
Nucleofection of siRNAs into CML Primary Cells
CML primary cells transfected by Nucleofection
Application Note

By Michaela Merkerova and Hana Bruchova, Inst. of Hematology and Blood Transfusion, Prague, Czech Republic

Comparative analysis of transfection methods for siRNA delivery into patient derived CML primary cells. Nucleofector Technology represented the best and only suitable non-viral method for transfection of CML primary cells.

       Review


Authenticated, low-passage Cell Lines Optimize Cancer Research

Cell lines at higher passage numbers experience changes in cell morphology, response to stimuli, growth rates, gene expression and transfection capacities. Therefore it is crucial to use lower-passage number cells especially when working with cancer cell lines as these cells are even more susceptible to changes with long term subculturing.

       Product Information

Nucleofector 96-well Shuttle
Whether you are studying the up- and down-regulation of cancer genes in difficult-to-transfect or standard cancer cells: Nucleofector Technology is the ideal tool for the non-viral transfection of substrates such as DNA or siRNA into cancer cells, combined with high flexibility – from single up to
96-well format.

       Presentation

View Presentation
From cancer cell lines to primary cancer cells, excellent transfection results can be achieved using Nucleofector Technology for both DNA and siRNA.

Learn more about Overcoming Hurdles in Cancer Cell Transfection in this presentation.

       Related FAQs

Our frequently asked questions list contains useful tips and hints as well as background information on the Nucleofection of cancer cells.

       Related Citations

More than 650 citations attest to the Nucleofector Technology being a valuable tool to accelerate your cancer research.

View List to see a selection of them.
To see all citations visit our Citations Database and select the Research Area 'Cancer Research'.

Re-optimized Cancer Cell Line OPs

for COS-7, U-937, Jurkat,
PC-12.

Ensuring even better 
transfection results!

Download Cancer Flyer


Download Cancer Flyer

Meetings & Shows

amaxa Meeting Calendar for April to July 2008.
amaxa Website


Next Online User Webinar

Attend amaxa's next online user webinar on

'Nucleofection of
 Stem Cells'

Register here!

Next Issue

amaxa eNews #6
coming in June 2008

Hot Topic: Protein Expression & Production

Subscribe

Subscribe here to receive future issues of amaxa eNews.
Invite a friend

Recommend amaxa's eNews to a friend or colleague.
You have received this e-mail because you have subscribed to amaxa eNews.
If you do no longer wish to receive amaxa eNews please unsubscribe here or log into your amaxa account to manage your subscriptions.

The Nucleofector Technology, comprising Nucleofection Process, Nucleofector Device, Nucleofector Solutions, Nucleofector 96-well Shuttle System and Nucleocuvette plates and modules is covered by patent and/or patent pending rights owned by amaxa AG.

amaxa, Nucleofector, nucleofection, maxGFP, 96-well Shuttle and Nucleocuvette are either registered trademarks or trademarks of amaxa AG in the U.S. and/or Germany and/or other countries. ATCC‚ and the ATCC Catalog Marks are trademarks of ATCC used under License. Other product and company names mentioned herein are the trademarks of their respective owners.

amaxa disclaims all warranties, whether expressed or implied, including any warranty as to the quality, accuracy, safety, or suitability of the information provided in this e-newsletter for any particular purpose. Any use of the information contained on any page of this e-newsletter is evidence of agreement with these terms of use.